Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection.

Harrer T, Harrer E, Kalams SA, Elbeik T, Staprans SI, Feinberg MB, Cao Y, Ho DD, Yilma T, Caliendo AM, Johnson RP, Buchbinder SP, Walker BD.

AIDS Res Hum Retroviruses. 1996 May 1;12(7):585-92.

PMID:
8743084
2.

Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load.

Harrer T, Harrer E, Kalams SA, Barbosa P, Trocha A, Johnson RP, Elbeik T, Feinberg MB, Buchbinder SP, Walker BD.

J Immunol. 1996 Apr 1;156(7):2616-23.

PMID:
8786327
3.

Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection.

Hay CM, Ruhl DJ, Basgoz NO, Wilson CC, Billingsley JM, DePasquale MP, D'Aquila RT, Wolinsky SM, Crawford JM, Montefiori DC, Walker BD.

J Virol. 1999 Jul;73(7):5509-19.

4.

Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.

Pilgrim AK, Pantaleo G, Cohen OJ, Fink LM, Zhou JY, Zhou JT, Bolognesi DP, Fauci AS, Montefiori DC.

J Infect Dis. 1997 Oct;176(4):924-32.

PMID:
9333150
5.

Kinetics of immune functions and virus replication during HIV-1 infection.

Pontesilli O, Klein MR, Kerkhof-Garde SR, Pakker NG, de Wolf F, Schuitemaker H, Miedema F.

Immunol Lett. 1997 Jun 1;57(1-3):125-30.

PMID:
9232438
6.

Studies in subjects with long-term nonprogressive human immunodeficiency virus infection.

Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, Demarest JF, Montefiori D, Orenstein JM, Fox C, Schrager LK, et al.

N Engl J Med. 1995 Jan 26;332(4):209-16.

7.

Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors.

Bradney AP, Scheer S, Crawford JM, Buchbinder SP, Montefiori DC.

J Infect Dis. 1999 May;179(5):1264-7.

PMID:
10191234
8.

Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors.

Betts MR, Krowka JF, Kepler TB, Davidian M, Christopherson C, Kwok S, Louie L, Eron J, Sheppard H, Frelinger JA.

AIDS Res Hum Retroviruses. 1999 Sep 1;15(13):1219-28.

PMID:
10480635
10.

Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics.

Klein MR, van Baalen CA, Holwerda AM, Kerkhof Garde SR, Bende RJ, Keet IP, Eeftinck-Schattenkerk JK, Osterhaus AD, Schuitemaker H, Miedema F.

J Exp Med. 1995 Apr 1;181(4):1365-72.

11.

Effector HIV-specific cytotoxic T-lymphocyte activity in long-term nonprogressors: associations with viral replication and progression.

Keoshkerian E, Ashton LJ, Smith DG, Ziegler JB, Kaldor JM, Cooper DA, Stewart GJ, Ffrench RA.

J Med Virol. 2003 Dec;71(4):483-91.

PMID:
14556259
12.

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.

Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, Bilska M, Craiu A, Zheng XX, Krivulka GR, Beaudry K, Lifton MA, Nickerson CE, Trigona WL, Punt K, Freed DC, Guan L, Dubey S, Casimiro D, Simon A, Davies ME, Chastain M, Strom TB, Gelman RS, Montefiori DC, Lewis MG, Emini EA, Shiver JW, Letvin NL.

Science. 2000 Oct 20;290(5491):486-92.

13.
14.

HIV-specific cytotoxic T-lymphocyte activity in immunologically normal HIV-infected persons.

Bernard NF, Pederson K, Chung F, Ouellet L, Wainberg MA, Tsoukas CM.

AIDS. 1998 Nov 12;12(16):2125-39.

PMID:
9833853
15.

Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.

Corey L, McElrath MJ, Weinhold K, Matthews T, Stablein D, Graham B, Keefer M, Schwartz D, Gorse G.

J Infect Dis. 1998 Feb;177(2):301-9.

PMID:
9466515
17.

Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection.

Kim JH, Mascola JR, Ratto-Kim S, VanCott TC, Loomis-Price L, Cox JH, Michael NL, Jagodzinski L, Hawkes C, Mayers D, Gilliam BL, Birx DC, Robb ML.

AIDS Res Hum Retroviruses. 2001 Jul 20;17(11):1021-34.

PMID:
11485619
18.

Spreading of HIV-specific CD8+ T-cell repertoire in long-term nonprogressors and its role in the control of viral load and disease activity.

Propato A, Schiaffella E, Vicenzi E, Francavilla V, Baloni L, Paroli M, Finocchi L, Tanigaki N, Ghezzi S, Ferrara R, Chesnut R, Livingston B, Sette A, Paganelli R, Aiuti F, Poli G, Barnaba V.

Hum Immunol. 2001 Jun;62(6):561-76.

PMID:
11390031
19.

Neutralizing antibodies against autologous human immunodeficiency virus Type 1 isolates in patients with increasing CD4 cell counts despite incomplete virus suppression during antiretroviral treatment.

Sarmati L, d'Ettorre G, Nicastri E, Ercoli L, Uccella I, Massetti P, Parisi SG, Vullo V, Andreoni M.

Clin Diagn Lab Immunol. 2001 Jul;8(4):822-4.

20.

Anti-HIV type 1 cytotoxic T lymphocyte effector activity and disease progression in the first 8 years of HIV type 1 infection of homosexual men.

Rinaldo CR Jr, Beltz LA, Huang XL, Gupta P, Fan Z, Torpey DJ 3rd.

AIDS Res Hum Retroviruses. 1995 Apr;11(4):481-9.

PMID:
7632463

Supplemental Content

Support Center